

Attorney's Docket No. 12504.348

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

United States Patent Application

Title: SYNTHESIS OF PHENSTATIN AND
PRODRUGS THEREOF

Inventor: Pettit et al.

Serial No.: 09/582,952

Filing Date: September 5, 2000

Conf. No.: 4536

Group Art Unit: 1621

Examiner: Barts, Samuel A.

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and MPEP 2001.06(a), Applicant hereby submits an Information Disclosure Statement ("IDS") to provide information revealed in the European search report dated March 10, 2003 for a related foreign application based on the same international application no. PCT/US99/00475. Attached to this IDS is Form PTO/SB/08A listing the cited documents, and a copies of the documents are enclosed.

Pursuant to 37 C.F.R. §§ 1.97 (g) and 1.97 (h), this disclosure statement should not be construed as a representation that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This IDS is being submitted prior to the mailing of a first Office Action after the filing of a request for continued examination.

INFORMATION DISCLOSURE STATEMENT
U.S. Patent Application Serial No. 09/582,952

It is believed that this disclosure complies with the requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98, and the Manual of Patent Examining Procedure § 609. If for some reason the Examiner considers otherwise, the undersigned respectfully requests that she be called so that any deficiencies can be remedied.

Dated: March 30, 2004.

Respectfully submitted,

FENNEMORE CRAIG, P.C.



Susan Stone Rosenfield

Reg. No. 36,287

3003 N. Central Avenue, Suite 2600

Phoenix, Arizona 85012-2913


Tel: (602) 916-5317

Fax (602) 916-5517

Express Mail Label No. EV 352474574 US

Date of Deposit 3-30-04

I hereby certify that this paper and all documents and any fee referred to herein are being deposited on the date indicated above with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, postage prepaid and addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Louis A. Lofredo, Legal Assistant

3-30-04
Date of Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1**

of **2**

Complete if Known

Application Number	09/582,952
Filing Date	September 5, 2000
First Named Inventor	Pettit et al.
Group Art Unit	1621
Examiner Name	Barts, Samuel A.
Attorney Docket Number	12504.348

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PETTIT, G. R. et al.; "Antineoplastic agents. 379. Synthesis of Phenstatin Phosphate.", Journal of Medicinal Chemistry, Vol. 41, No. 10, pp. 1688-1695 (May 7, 1998).	
		GSCHWEND, DANIEL A. et al., "Specificity in Structure-Based Drug Design: Identification of a Novel, Selective Inhibitor of Pneumocystis carinii Dihydrofolate Reductase," PROTEINS: Structure, Function, and Genetics, Vol. 29, No. 1, pp. 59-67 (1997).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.